Combination of oral idarubicin and prednimustine in advanced breast cancer: A phase II study

European Journal of Cancer Part A

Volumn 33, Issue 2, 1997, Pages 312-315

  Barnadas, A ^a   Mendiola, C ^b   Casado, A ^c   Villar, A ^d   Jimeno, J ^e,f   Clerigue, M ^e,g   Rosell, R ^a   Diaz Rubio, E ^c   Cortes Funes H ^b   De Paredes, M García ^e  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL ARNAU DE VILANOVA   (Spain)

^e AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^f PHARMAMAR S A   (Spain)

^g FAES R + D   (Spain)

Author keywords

Advanced breast cancer; Chemotherapy; Idarubicin; Prednimustine

Indexed keywords

IDARUBICIN; PREDNIMUSTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030995156     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00372-3     Document Type: Article

References (15)

1. Hollingshead LM, Faulds D. Idarubicin. A review of its pharmacodynamic and pharmacokinetics properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991, 42, 2690-2719.
2. Cersomino RJ. Idarubicin: an anthracycline antineoplastic agent. Clin Pharm 1992, 11, 152-167.
3. Riggs ChE. Antitumor antibiotics and related compounds. In Perry MC, ed. The Chemotherapy Sourcebook. Baltimore, William and Wilkins, 1992, 318-358.
4. Lasota WS, Valeriola DL, Piccart MJ. Potential role of oral anthracyclines in older patients with cancer. Drugs Aging 1994, 4, 392-402.
5. Martoni A, Piana E, Guaraldi M, et al. Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer. Oncology 1990, 47, 427-432.
6. Lopez M, Contegiacomo A, Vici P, et al. A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer 1989, 64, 2431-2436.
7. Dorr RT, Shipp NG, Lee KM. Comparison of cytotoxicity in heart cells and tumor cells exposed to DNA intercalating agents in vitro. Anti-Cancer Drugs 1991, 2, 27-33.
8. Lopez M, Vici P, Carpano S, et al. Combination chemotherapy with oral idarubicin and cyclophosphamide for metastatic breast cancer. J Cancer Res 1991, 117, 61-64.
9. Kolaric K, Melchl Z. Combination of idarubicin and cyclophosphamide administered orally in untreated postmenopausal breast cancer patients. Oncology 1991, 48, 93-96.
10. Pronzato P, Bertelli G, Amoroso D, et al. Oral chemotherapy with idarubicin plus cyclophosphamide in advanced breast cancer. Chemotherapy 1991, 37, 449-453.
11. Lober J, Mouridsen HT, Christiansen IE, Dombernowsky P, Mattsson W, Rorth M. A phase III trial comparing prednimustine to chlorambucil plus prednisolone in advanced breast cancer. Cancer 1983, 52, 1570-1576.
12. Mouridsen HT. Prednimustine in advanced breast cancer. A review. Semin Oncol 1986, 13, 27-31.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981, 47, 207-214.
14. Chabner BA. Anticancer drugs. In De Vita VT, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology. Philadelphia, Lippincott Company, 1993, 325-417.
15. Alberto P. Phase II study of an oral combination of doxifluridine, prednimustine and idarubicin for first line treatment of advanced breast cancer. Ann Oncol 1993, 4, 423-425.